Our platform recreates key aspects of human tissue biology and generates functional evidence to evaluate efficacy, safety, and candidate performance earlier. For AI drug discovery, Anivance bridges computational discovery and human-relevant physical experimentation, generating structured biological data that can inform subsequent model refinement, experimental design, and development decisions
Conversations with Mayo Clinic and ASU experts helped us sharpen how human-relevant evidence can support better drug development decisions and opened new ways for us to think about validation and collaboration.
"One of the most valuable parts of the Health Care Accelerator was the opportunity to look at our technology through the lens of clinical and translational needs."
Guan Yu Chen, Ph.D.
Founder and CEO, Anivance AI